Feasibility Trial of CBT for Depersonalisation in Psychosis
A Brief Cognitive Behavioural Therapy (CBT) Intervention for Depersonalisation/Derealisation in Psychosis: a Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE5 8AZ
- PICUP clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- current experience of psychotic symptoms,
- meeting threshold for DP/DR disorder (scores greater than 70 on Cambridge Depersonalization Scale (CDS)).
Exclusion Criteria:
- insufficient capacity to provide informed consent;
- insufficient proficiency in English (spoken and written) to engage in CBT;
- a primary diagnosis of intellectual disability, head injury, substance misuse or organic cause for psychosis;
- those currently engaging in CBT or other psychotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: CBT for DP
Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
|
In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
|
|
Placebo Comparator: Treatment as usual
Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
|
Treatment as usual - in most cases case management/care coordination and may include medication
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of intervention ( including recruitment rates, acceptance rates, drop outs)
Time Frame: 10 weeks
|
Feasibility estimates of delivering the intervention including recruitment rates, acceptance rates, drop outs.
|
10 weeks
|
|
Depersonalisation score (Score on the Cambridge Depersonalisation Scale)
Time Frame: 10 weeks
|
Score on the Cambridge Depersonalisation Scale
|
10 weeks
|
|
Acceptability of intervention (Satisfaction and attrition rates)
Time Frame: 10 weeks
|
Satisfaction and attrition rates
|
10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression (Score on Beck Depression Inventory)
Time Frame: 10 weeks
|
Score on Beck Depression Inventory
|
10 weeks
|
|
Anxiety (Score on Beck Anxiety Inventory)
Time Frame: 10 weeks
|
Score on Beck Anxiety Inventory
|
10 weeks
|
|
Psychosis (Score on the Psychotic Symptom Rating Scale (PSYRATS)
Time Frame: 10 weeks
|
Score on the Psychotic Symptom Rating Scale (PSYRATS)
|
10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Simone Farrelly, PhD, King's College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Protocol 141216v3
- 15/LO/0081 (Other Identifier: Research Ethics Committee)
- 166784 (Other Identifier: IRAS)
- R&D2015/017 (Other Identifier: R&D office)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.